Late onset systemic lupus erythematosus with severe hypercalcaemia

Late-onset SLE is a rare condition in elderly patients, and its presentation can be atypical. Prior research has shown that SLE typically manifests with a range of immunological and clinical features. However, hypercalcaemia is not commonly associated with SLE. It was already known that hypercalcaemia can result from various causes, including malignancy or endocrine disorders. That uncertainty drove the need to explore the link between SLE and hypercalcaemia. No prior work had resolved the role of fibroblast growth factor 23 (FGF23) in this context. This gap motivated the investigation of whether FGF23 might be involved in SLE-related hypercalcaemia. The study aimed to clarify the relationship between SLE activity and calcium metabolism. Understanding these mechanisms could help in managing atypical SLE cases.

The aim of this case report was to investigate the connection between late-onset SLE and severe hypercalcaemia. The researchers focused on a 76-year-old patient with unexplained high calcium levels. They wanted to determine if SLE could be the underlying cause of the hypercalcaemia. The motivation came from the patient's atypical presentation and the absence of more common causes. The team sought to evaluate the patient's immunological profile and calcium-related biomarkers. They also aimed to assess the response of these markers to steroid treatment. The study was designed to track changes in FGF23 and parathyroid hormone levels over time. This approach helped to explore the potential role of FGF23 in SLE-induced hypercalcaemia.

The researchers conducted a clinical case analysis of a 76-year-old female patient. They collected data on her symptoms, laboratory findings, and treatment response. The patient's blood work included measurements of calcium, FGF23, and intact parathyroid hormone. They also tested for antinuclear antibodies and anti-dsDNA to confirm SLE. The team monitored the patient's disease activity and calcium levels over time. They compared the rate of change between FGF23 and parathyroid hormone. The study utilized serial blood tests to track these biomarkers. The researchers documented the patient's response to steroid therapy to evaluate treatment effectiveness.

The patient was diagnosed with late-onset SLE based on laboratory findings and clinical symptoms. She presented with severe hypercalcaemia and low FGF23 and parathyroid hormone levels. Her condition improved after steroid treatment, which correlated with reduced disease activity. FGF23 levels increased more rapidly than parathyroid hormone during follow-up. This pattern suggested a possible role for FGF23 in the hypercalcaemia mechanism. The patient's kidney function was impaired, which may have contributed to the calcium imbalance. The response to steroids indicated that disease activity influenced calcium metabolism. These findings support the hypothesis that FGF23 may be involved in SLE-related hypercalcaemia.

The authors suggest that FGF23 may play a role in the pathogenesis of hypercalcaemia in SLE. The observed changes in FGF23 levels occurred in parallel with disease activity and treatment response. The faster increase in FGF23 compared to parathyroid hormone supports this idea. However, the exact mechanism remains unclear and requires further investigation. The study highlights the importance of monitoring FGF23 in SLE patients with hypercalcaemia. The findings may help in understanding atypical SLE presentations. The researchers propose that FGF23 could be a useful biomarker in these cases. These conclusions are based on the observed clinical and laboratory data from this single patient.